The infectious disease in vitro diagnostics market size is expected to grow from US$ 45.69 billion in 2024 to US$ 76.71 billion by 2031; it is projected to register a CAGR of 7.7% during 2025-2031. The increasing prevalence of infectious diseases and strategic developments by key players are noteworthy factors contributing to the expansion of the infectious disease in vitro diagnostics market size. However, the inadequate reimbursement scenario hinders the infectious disease in vitro diagnostics market growth.

Technological advancements involving the development and integration of molecular diagnostics and automation systems enhance the accuracy, speed, and accessibility of infectious disease detection. Below are a few instances:

- In June 2024, MP Biomedicals introduced a new line of rapid immunochromatographic assays for Helicobacter pylori, Salmonella typhi, and Vibrio cholerae, intended for point-of-care in resource-constrained environments.

- In June 2024, Roche gained FDA Emergency Use Authorization (EUA) for its cobas liat multiplex PCR panel updated to detect SARS-CoV-2, influenza A/B, and RSV simultaneously, advancing syndromic respiratory infection management in less than 20 minutes.

- In July 2024, Sherlock Biosciences initiated clinical trials for its CRISPR-based over-the-counter (OTC) test for gonorrhea and chlamydia in May 2024, with an eye toward a 2025 launch. APEX-TB, integrating machine learning from AI and nanotechnology, was also launched to provide accurate, real-time molecular diagnostics using portable devices.

- In June 2024, QIAGEN introduced 35 new wet-lab tested digital PCR Microbial DNA Detection Assays to its digital PCR (dPCR) platform QIAcuity, noticeably strengthening its capabilities in microbial research.

These advancements are part of a larger movement toward decentralized, user-centric, and fast diagnostic technologies guiding the future of infectious disease care. This is expected to contribute to the growth of the infectious disease in vitro diagnostics market in the coming years.

End User -Based Insights

Based on end user, the infectious disease in vitro diagnostics market is segmented into hospitals and clinics, diagnostics laboratories, blood bank, and others. The hospitals and clinics segment held the largest infectious disease in vitro diagnostics market share in 2024. The need for accurate, timely diagnosis in hospitals and clinics is rising steadily due to frequent outbreaks of Lassa fever, cholera, tuberculosis, and malaria. The soaring patient load and demand for quality care have pushed hospitals to adopt more sophisticated diagnostic tools, including molecular diagnostics. Increased government funding, donor support, and infrastructure improvements in secondary and tertiary hospitals further boost the adoption of IVD products. Integrating IVD in hospital protocols improves patient outcomes, reduces unnecessary antibiotic use, and ensures better management of infectious diseases in urban and rural health centers, thereby fueling the infectious disease in vitro diagnostics market growth.

The World Health Organization and Mexico's Ministry of Health's National Institute of Respiratory Diseases are among the primary and secondary sources referred to while preparing the infectious disease in vitro diagnostics market report.